Abstract | The discovery of disorders that are associated with antibodies to neuronal cell-surface proteins has led to a paradigm shift in our understanding of CNS autoimmunity. These disorders can occur in patients with or without cancer-often children or young adults who develop psychosis, catatonic or autistic features, memory problems, abnormal movements, or seizures that were previously considered idiopathic. The autoantigens in such cases have crucial roles in synaptic transmission, plasticity and peripheral nerve excitability. Patients can be comatose or encephalopathic for months and yet fully recover with supportive care and immunotherapy. By contrast, disorders in which the antibodies target intracellular antigens, and in which T-cell-mediated irreversible neuronal degeneration occurs, show a considerably poorer response to treatment. In this article, we review the various targets of neuronal antibodies, focusing predominantly on autoantigens located on the cell surface or synapses-namely, N-methyl-d-aspartate receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, γ-aminobutyric acid receptors, leucine-rich glioma-inactivated protein 1, contactin-associated protein-like 2, and metabotropic glutamate receptors. We also provide an algorithm to identify and assess antibodies that bind to cell-surface and synaptic antigens.
Introduction
Antibodies that target neuronal epitopes were first recog nized in patients with paraneoplastic neuronopathy, cere bellar degeneration, or encephalitis. In these dis orders, the target antigens are nuclear or cytoplasmic pro teins, such as Hu, Yo and Ma2, to which antibodies have limited accessibility. Accordingly, many of these anti bodies are not directly pathogenic, but instead indicate a Tcellmediated immune response against the corres ponding neuronal antigens ( Figure 1) . A second group of antibodyrelated brain disorders involves antibodies that target intracellular synaptic proteins, such as 65 kDa glutamic acid decarboxylase (GAD65) and amphiphysin. These antigens might be vulnerable to antibodymediated disruption during synaptic vesicle fusion and reuptake, but whether Tcellmediated pathogenic mechanisms are more important than antibodymediated mechanisms remains a topic of debate ( Figure 1 ).
More recently, a third group of brain disorders was identified in which the antibodies target cellsurface or synaptic proteins and are associated with encephalitis ( Figure 1 ). The antigens include the Nmethyldaspartate receptor (NMDAR); 1 the αamino3hydroxy5 methyl4isoxazolepropionic acid receptor (AMPAR); 2 the γaminobutyric acid receptorB (GABA B receptor); 3 two protein targets that were previously thought to be voltagegated potassium channels (VGKCs) but are now known to be leucinerich gliomainactivated protein 1 (LGI1) and contactinassociated proteinlike 2 (Caspr2); [4] [5] [6] the glycine receptor (GlyR); 7 and the metabotrop ic gl utamate receptor mGluR5. 8 The encephalitides associated with antibodies against cellsurface antigens differ from those related to intra cellular antigens in several important respects. First, the cellsurface target antigens are disrupted by the antibodies. Second, the association with malignancy is much less con sistent. Third, symptoms can more commonly be reversed with treatment. Last, the symptoms relate to the disrup tion of the target antigen. Exceptions to these rules are the disorders associated with cerebellar degeneration and antibodies against cellsurface antigens, including mGluR1 and voltagegated calcium channels (VGCCs). The cere bellar degeneration that results from immune responses to these antigens is poorly responsive to immuno therapy, and the presence of VGCC anti bodies almost always indicates an underlying smallcell lung cancer (SCLC). Antibodies to VGCC also occur in Lambert-Eaton myasthenic syn drome, which is responsive to immunotherapy and may occur with or without cancer.
This Review describes the targets of neuronal auto antibodies, focusing particularly on cellsurface and synap tic autoantigens, and provides an algorithm for interpretation of results of antibody tests.
Nuclear and cytoplasmic antigens
The strong association of some neuronspecific anti bodies with cancer, and the expression of the target antigens by neurons and cancer cells, led to these antibodies being collectively termed 'paraneoplastic' or 'onconeuronal' antibodies. The main neurological syndromes, the asso ciated cancers, and the functions of the target antigens of these antibodies are shown in Table 1 .
In these disorders, the antibodies are found in the patient's CNS, but are not thought to be directly path ogenic. For example, studies of patients with Hu anti bodies showed IgG bound to the nuclei of neurons, and the antibodies were enriched in the cerebrospinal fluid (CSF) owing to intrathecal antibody synthesis. 9 Injection of Hu antibodies into experimental animals, however, did not cause symptoms. 10 Furthermore, immunization of mice with Hu resulted in the presence of Hu anti bodies in serum and anti tumour activity, but no neuro logical consequences. 11, 12 Interestingly, although 20% of patients with SCLC have serum Hu antibodies, less than 0.01% of patients with SCLC develop paraneoplastic neurologic al syndromes. 13 Tcellmediated mechanisms might be responsible for disorders associated with antibodies to nuclear or cytoplasmic antigens. Indeed, Tcell responses to HuD have been demonstrated in patients with paraneoplastic encephalomyelitis.
14 Brain or peripheral nerve tissues from these patients show more infiltration by T lympho cytes than by B lymphocytes, 9, 15 and T cells are found in close contact with neurons that express MHC class I molecules. 16 Immunization of mice with peptides derived from HuD also gives rise to cytotoxic T lymphocytes that target Hu, although these animals do not develop neurologic al symptoms. 17 Expression of Hu in SCLC is thought to trigger the Hudirected autoimmune response-a hypothesis that is supported by the presence of Hu antibodies in trans genic mice that are predisposed to develop SCLC. 18 Normal mice, but not HuDnull mice, have profound tolerance for Hu, and this type of tolerance probably protects most patients with SCLC from autoimmune symptoms. 19 A substantial proportion of HuDreactive CD8 + lymphocytes from patients are type 2, which are less cytotoxic than type 1 CD8 + lymphocytes. This finding might account for the lack of cytotoxic neuronal activity in animal models of, and in most patients with, SCLC. 20 The mechanism through which this tolerance has been overcome in patients who present with autoimmune symptoms is unknown.
Tcellmediated mechanisms that target other intra cellular antigens have also been proposed. 21 A postmor tem study of patients with antibodies against collapsin response mediator protein 5 found evidence of Tcell mediated pathology, 22 and postmortem studies of patients with antibodies against Yo (also known as CDR2) showed Tcell infiltration of the cerebellum with extensive loss of Purkinje cells, but not deposits of IgG or complement, or Bcell infiltrates. [23] [24] [25] Two reports described cytotoxic Tcell responses to Yo in patients with Yo antibodies, 26, 27 although these findings could not be replicated in a sub sequent study. 28 In one study, Yo antibodies were taken up by cerebellar neurons in slice cultures and triggered cell death, 29 whereas in other studies, Yo antibodies injected Key points ■ Antibodies that target neuronal antigens are becoming increasingly recognized ■ Antibodies to intracellular neuronal antigens may mark a T-cell response that targets neurons ■ Antibodies to cell-surface and synaptic antigens are associated with seizures and psychosis, as well as disorders of memory, behaviour, cognition and movement; such antibodies may be directly pathogenic ■ Many patients with antibodies to cell-surface antigens respond to treatment ■ Assessment of clinical phenotype and analysis of serum and cerebrospinal fluid are crucial for identification of known and novel autoantibodies intraventricularly 30 or intraperitoneally in combination with blood-brain barrier disruption 31 were taken up by Purkinje cells but did not cause neuronal death.
In summary, antibodies to intracellular cytoplasmic and nuclear antigens do not seem to be directly pathogenic but, rather, are markers of Tcell responses that target neurons. Response to therapy tends to be poor in neuro logical disorders associated with these auto antibodies, perhaps owing to irreversible neuronal death.
Intracellular synaptic antigens
GAD65 and amphiphysin are intracellular synaptic antigens ( Table 2 ). GAD65 is the form of glutamatic acid decarboxylase that is concentrated in presynaptic terminals, 32 and amphiphysins are proteins of the BAR su perfamily-molecules that are crucial for clathrin mediated endocytosis, which is required for recycling of synaptic vesicles. 33 Unlike the antigens discussed in the previous section, the epitopes of GAD65 and amphiphy sin can be exposed to antibodies during synaptic vesicle fusion and reuptake ( Figure 1 ).
GAD65 antibodies are associated with stiffperson syndrome (SPS) and cerebellar ataxia, but have also been reported in other syndromes such as limbic encephali tis and epilepsy. [34] [35] [36] Part of this diversity could be due to the common association of GAD65targeted antibodies with other autoantibodies. [2] [3] [4] Amphiphysin antibodies are also found in association with SPS, particularly in patients with breast cancer. 37, 38 Evidence exists that both cellmediated and antibody mediated mechanisms underlie the pathogenic effects of GAD65 antibodies. GAD65 antibodies from most patients with SPS decrease the synthesis of GABA in tissue extracts, but whether this response occurs in vivo is unclear. 39 GAD65 antibodies from some patients with SPS have also been reported to increase the excitability of spinal cord neurons and cause abnormal spontaneous motor neuron discharges-findings that are of potential relevance to SPS. 40 A notable study in mice, however, suggests that T cells are the primary pathogenic drivers in disorders associated with GAD65 antibodies. For this study, the researchers generated mice with a Tcell response to GAD65, and then isolated GAD65specific T cells and transferred these Tcell clones to GAD65 naive mice. 41 The immunized mice developed encephalo myelitis, and transfer of clones of GAD65specific T cells to naive mice caused similar neurological symptoms. 42 Interestingly, transfer of the T cells to mice lacking B cells produced similar symptoms, the only difference being the Amphiphysin antibodies might be pathogenic. Passive transfer to mice of either IgG from two patients with these antibodies or affinitypurified amphiphysin antibodies resulted in stiffness and muscle spasms in the animals. 43, 44 The antibodies alter GABAergic neuro transmission, possibly by reducing the surface expression of sodiumpotassium-chloride cotransporter 1. 45 The antibodies are internalized in presynaptic terminals of spinal inhibitory neurons, 44 and disrupt inhibitory synaptic transmission in the spinal cord and the recycling of inhibitory synap tic vesicles. Conversely, postmortem study of a patient with a syndrome associated with amphiphysin antibodies showed a CD8predominant Tcell infiltrate in the brain, spinal cord and dorsal root ganglia. 38 Overall, therefore, intracellular synaptic antigens are important for the function of inhibitory synapses. Although disruption of these proteins by antibodies might be responsible for some of the symptoms seen in patients, Tcellmediated mechanisms also seem to be involved.
Cell-surface and synaptic antigens
Antibodies against cellsurface and synaptic antigens are being identified with increasing frequency ( Table 2 ). The associated syndromes often mimic genetic or pharmaco logical disruption of the target antigens. Studying the functions of these important proteins will, therefore, prove helpful in improving our understanding of patients' sy mptoms and the functions of these proteins in humans.
NMDA receptors
Since its discovery in 2007, 1 the disorder associated with NMDAR antibodies has been reported in over 500 patients, including children, 46 women with or without tera toma, and men. 47 In the California Encephalitis Pro ject, which focuses on diagnosis of encephalitis of unclear aetiology, the incidence of encephalitis associated with NMDAR antibodies currently surpasses that of encephalit is with viral aetiology identified in young patients. 48 NMDAR antibodies are associated with a characteris tic syndrome that frequently includes prodromal symp toms resembling a viral illness, followed in a few days or weeks by prominent psychiatric symptoms, catatonia, agita tion, seizures, decreased level of consciousness, abnor mal movements, and autonomic instability. 49 This acute stage is followed by a prolonged phase of recovery, during which executive functions are altered and psychiatric symptoms often resurface. About 75% of patients ulti mately recover, usually slowly, over a period of months. 47 These symptoms resemble those associated with NMDAR antagonists, such as phencyclidine. 47 The only tumour that is strongly associated with anti NMDAR encephalitis is ovarian teratoma. 50 Prompt removal of this tumour, together with immuno therapy, is associated with morerapid improvement of the encephalitis. 47 The NMDAR is crucial for synaptic plasticity, learn ing, and memory. NMDAR antibodies produce effects similar to genetic disruption of the NMDAR. Mice with partial genetic disruption of the NR1 subunit of the NMDAR-the subunit that is the primary target of the antibodies-show impaired learning and stereotyped behavioural abnormalities that are suggestive of schizo phrenia, and mice with profound disruption of NR1 die early of respirato ry failure. 51 Several lines of evidence support a pathogenic role for NMDAR antibodies in patients. First, these anti bodies decrease the levels of synaptic NMDAR and dis rupt NMDARdependent synaptic currents in cul tured neurons. 49, 52 These effects are reversible and depend on antibodymediated capping and internaliza tion of the receptor, as Fab fragments do not have these effects. 52 Second, patients with NMDAR antibodies have a considerably better prognosis than those with, for example, Hu antibodies, and most patients recover. 47 Patients with NMDAR antibodies may even recover after many months of coma, 53 consistent with functional dis ruption of synaptic transmission rather than irrever sible T-cellmediated neuronal damage. Third, pathology studies have shown antibody deposition in patients' brains, but without complement or substantial neuronal death. 50 Last, infusion of antibodies into rodent brains results in decreased levels of synaptic NMDARs, increased gluta mate release, impaired glutamate regulation, and increased corticomotor excitability. 54, 55 Proteins related to the VGKC Shaker family Antibodies that bind the VGKC complex have been detected in patients with peripheral nerve hyperexcit ability, encephalitis, Morvan syndrome, or various other dis orders. 56, 57 Initial reports suggested that patients' antibodies bind to the VGKCs Kv1.1 and Kv1.2. 56,58 Recent studies, however, have shown that LGI1 and Caspr2 are the main autoantigens. [4] [5] [6] A third autoantigen that has been implicated in a minority of patients is contactin2, 6 a cell adhesion protein that is expressed on neuronal axons and myelinating cells. However, anti bodies against contactin2 usually occur in association with those tar geting LGI1 or Caspr2, and have been identified in other disorders, 59 raising doubts about the importance of these antibodies.
LGI1 is a secreted synaptic protein that binds to pre synaptic ADAM23 (disintegrin and metalloprotein ase domaincontaining protein 23) and postsynaptic ADAM22, and associates with and regulates Kv1.1 and Kv1.2, as well as AMPARs. 60 Human LGI1 mutations result in autosomal dominant lateral temporal lobe epilepsy. 61 Caspr2 is a transmembrane axonal protein of the neurexin IV superfamily that is localized to the juxta paranode of myelinated axons. Its extracellular domain interacts with contactin2, 62 and it connects with the cyto skeleton via protein 4.1B (Figure 2 ). Caspr2, contactin2 and pro tein 4.1B are all necessary to concentrate Kv1.1 and Kv1.2 channels in the juxtaparanode. 63 This localization is important for the proper electrical functioning of axons, 64 although the mechanism by which Caspr2 concentrates Kv1.1 and Kv1.2 channels is unknown.
The discovery that proteins associated with Kv1.1 and Kv1.2, rather than the VGKCs themselves, are the auto antibody targets explains some of the diversity of symp toms among patients with these antibodies. For example, LGI1 is primarily a CNS protein, and LGI1 antibodies are associated with a CNS disorder.
LGI1
LGI1 antibodies are associated with limbic encephalitis, several types of seizures, and frequent hyponatraemia. 4, 6 The disorder is rarely paraneoplastic, and the response to treatment is often good. Some patients develop myoclonic movements which, in the setting of rapidly progressive encephalitis, can resemble Creutzfeldt-Jakob disease. 4, 65 The identification of LGI1 as a major target of socalled VGKC antibodies has clarified several aspects of the associ ated disorder. For example, the myoclonic move ments, which were previously underrecognized, have recently been characterized as faciobrachial dystonic sei zures 66 or, as we believe is more accurate, tonic seizures, 67 owing to the fact that these movements can also affect the lower extremities and are preceded by electro decremental EEG events. Interestingly, Lgi1null mice show several types of seizures, including tonic seizures, that result in a lethal phenotype.
68
LGI1 antibodies probably cause reversible CNS syn aptic dysfunction by several mechanisms. The anti bodies may prevent binding of LGI1 to the receptors that it regulates, or they might act on the LGI1-ADAM protein complex. Alternatively, LGI1 antibodies could disrupt currents mediated by Kv1.1 and Kv1.2, and/or impair AMPAR function, either indirectly by blocking LGI1mediated regu lation of these proteins or directly by disrupting the entire protein complex. A study involving application of serum from a patient with LGI1 antibodies to a hippo campal slice preparation showed effects similar to appli cation of a Kv1.1 and Kv1.2 antagonist, a finding that requires replication.
69

Caspr2
Caspr2 antibodies are associated with autoimmune encephalitis, peripheral nerve hyperexcitability, and Morvan syndrome. [4] [5] [6] 70 PNS manifestations can either precede or follow those in the CNS, in some cases by several years. Some patients with these antibodies have thymoma, but most do not have tumours. Response to immunotherapy is relatively good in most patients. 5 In some cases, symptoms overlapping those of myasthenia gravis develop, which can result in a complex syndrome with a superficial resemblance to motor neuron disease. 5 Mutations in the human gene encoding Caspr2 (CNTNAP2) are associated with autism, epilepsy, Tourette syn drome, cortical dysplasia, obsessive-compulsive dis order, Pitt-Hopkins syndrome, and other mental disabilities. [71] [72] [73] Mice with Caspr2 deletion show analo gous behavioural defects and symptoms. 74 Interestingly, common variants of the CNTNAP2 gene in healthy indivi duals are associated with abnormal language processing and are a risk factor for autism. 75 Caspr2 antibodies probably act by disrupting axonal potassium currents, although why the occurrence of PNS and CNS symptoms varies so widely among patients is unknown. Factors such as differences in time to establish ment of intrathecal antibody synthesis, or in the struc ture of tight, septatelike junctions of myelinating cells around the axons-structures that could limit the ability of antibodies to reach Caspr2-may explain this variability.
AMPA receptors
AMPAR antibodies are associated with limbic encepha litis and psychiatric symptoms, particularly in patients with tumours of the lung, breast or thymus. 2, 76, 77 AMPARs are ionotropic glutamate receptors that are important for excitatory neurotransmission. Structurally, they are hetero tetramers comprising various combinations of four subunits (GluR1-4). 78 Channels containing GluR1 and GluR2 are strongly regulated by activity, and are crucial for various forms of longterm synaptic plasticity. 78 Antibodies target the extracellular domains of GluR1 and GluR2 subunits of the receptor, and inhibit recep tor function through mechanisms similar to those of NMDAR antibodies, causing a reversible decrease in synap tic AMPARs and associated synaptic currents. 2 In a case series, most (nine of 10) patients responded to t reatment, but relapses were frequent. 2 
GABA B receptors
Patients with GABA B receptor antibodies present with limbic encephalitis that is characterized by a tendency towards severe seizures or status epilepticus. 3 Approxi mately half of the patients identified to date have SCLC cells (which express GABA B receptors), and anti bodies targeting GABA B receptors could be the most common autoantibody in patients with lung cancer and auto immune encephalitis. 79 The GABA B receptor is a G proteincoupled receptor that is expressed both pre synaptically and postsynaptically. Each receptor comprises a B1 subunit, which is important for agonist binding, and a B2 subunit, which is required for effect ing intracellular signalling. 80 The antibodies bind to the extracellular domain of the B1 subunit. Genetic or pharmaco logical disruption of the GABA B receptor results in seizures and cognitive impairment. 80 GABA B receptor antibodies probably act by disrupt ing receptor signalling, although they do not seem to mediate antibodymediated capping and internaliza tion, as has been demonstrated for antibodies against NMDARs and AMPARs (E. Lancaster et al., unpublished work). These differences may relate to the presynaptic location of many GABA B receptors.
Voltage-gated calcium channels VGCC antibodies are strongly associated with LambertEaton myasthenic syndrome, a neuromuscular disorder that typically causes proximal weakness and autonomic symptoms. These symptoms are attributed to auto immune disruption of neuromuscular transmission by antibodies to P/Qtype VGCCs. 81 Patients with VGCC antibodies may develop a cerebellar syndrome with or without the neuromuscular junction disorder. 82 VGCC antibodies can also occur in patients with other para neoplastic neurological disorders or in patients with cancer who do not have a neurological syndrome. 83 A recent study demonstrated VGCC antibodies in eight of 67 patients with sporadic, previously unexplained cere bellar degeneration. 84 VGCC antibodies are pathogenic at the neuromuscular junction and might also affect cere bellar neurotransmission. [85] [86] [87] Autopsy studies of patients with VGCC antibodyassociated cerebellar degeneration showed depletion of cerebellar P/Qtype VGCCs and antibody binding to the remaining channels, supporting a pathogenic role for VGCC antibodies in the CNS. 88 Figure 2 | Caspr2 interaction with juxtaparanodal proteins. Caspr2 is an axonal protein that binds contactin-2 in cis and trans orientations to organize the juxtaparanodal region. Caspr2 links to PDZ-binding proteins, and to the cytoskeleton via protein 4.1B. Caspr2 organizes Kv1 potassium channels in the juxtaparanodal region, although the underlying mechanism remains to be determined. Abbreviation: Caspr2, contactin-associated protein-like 2. Contactin-2
REVIEWS
Glycine receptors Antibodies against the α1 subunit of GlyR have been reported in a few patients with the syndrome progres sive encephalomyelitis with rigidity and myoclonus, 7 and in patients with symptoms of rigidity, exaggerated startle responses, diplopia, ataxia and myoclonus. 89, 90 Some of these patients responded to immunotherapy. No tumours have been associated with these antibodies. We have observed antibodies to GlyR subunits, including but not limited to α1, in patients with SPS (E. Lancaster et al., unpublished work). GlyR is an ionotropic receptor expressed in the brain stem and spinal cord. Activation of the receptor gener ates a chloride current that is inhibitory in most adult neurons, which have a low concentration of intracellular chlo ride. 91 GlyRs are composed of five subunits (α1-4 and β). Genetic disruption of GlyR subunits results in hereditary hyperekplexia (startle disease) in humans, 92 and similar disorders in mice, cattle and dogs. 93 Pharma cological inhibition of GlyR with strychnine results in rigidity, painful and disabling muscle spasms, and exagger ated startle responses. 94 The response of patients to immunotherapy and the resemblance of their symptoms to the genetic and pharmacologi cal syndromes argue in favour of a functional effect of the autoantibodies.
Metabotropic glutamate receptors
Antibodies targeting mGluR1 were first reported in two patients with cerebellar ataxia and a history of Hodgkin lymphoma. 95 Two patients with cerebellar ataxia but without Hodgkin lymphoma have subsequently been reported. 8, 96 Antibodies against mGluR5 were recently reported in two patients with Ophelia syndrome-a rare disorder involving psychiatric symptoms and cognitive and memory impairments that occurs in the setting of Hodgkin lymphoma. 97 These patients improved rapidly with antitumour therapy. 8 mGluR1 and mGlur5 constitute the group 1 mGluRs and show a high level of sequence homology with one another. 98 Despite this close homology, the receptors serve distinct functions: mGluR5 is important for long term depression of synapses in the hippocampus and for learning, 99 whereas mGluR1 is crucial for rapid synaptic transmission in the cerebellum. 100 Interestingly, patients' antibodies to mGluR1 or mGluR5 are always specific for one receptor type. 8, 95 Injection of mGluR1 antibodies near the cerebellum in rodents causes ataxia within 30 min. This ataxia reaches a maximum after 2-4 h and then resolves over 1 day. Moreover, application of mGluR1 antibodies to cerebel lar slices disrupts synaptic longterm depression, further supporting the notion that the cerebellum is the target site of these antibodies. 101 However, a postmortem study of a patient with mGluR1 antibodies showed a substan tial reduction in the number of Purkinje cells, with the surviving neurons having truncated dendritic arbours. 101 Purkinje cells express mGluR1, 102 but no Tcell infil trates were observed, so the mechanism by which these Purkinje neurons were lost is unclear.
Antibody tests
Caveats to interpretation Identification of novel autoantigens has resulted in the development of new diagnostic assays. Tests for intracel lular antigens frequently involve immunohisto chemistry per formed on tissue arrays and immunoblotting of recom binant proteins. Immunohistochemistry can have limi tations when several autoantibodies coexist in a single patient, but this technique has the advantage of detecting novel antibodies. By contrast, immunoblotting of recombinant proteins can be more specific, but does not identify novel antibodies.
The presence of antibodies against neuronal cell surface proteins was initially defined according to reac tivity of patient serum and CSF in three antigenbinding assays 49,52 -brain tissue optimized for presentation of cellsurface antigens, cultured dissociated neurons, and recombinant cells expressing the antigen of interest (cellbased assay). These criteria have since been simpli fied to the cellbased assay, sometimes using only the patient's serum and not the CSF. Because the readout is not quantitative, interpretation of the results or score depends on the experience of the researcher. Moreover, serum is often screened at low dilutions (<1:100), which can increase background artefacts and produce mis leading, falsepositive results despite rigorous controls (Figure 3 ). Serum that is weakly positive in the cellbased assay can test negative according to the other two cri teria. In such situations, the CSF is often negative and the associated symptoms are atypical (for example, related to mitochondrial disease, schizophrenia or prion disease), which all suggest a falsepositive result and call into question the clinical significance of low serum antibody levels (J. Dalmau, unpublished work). Therefore, as the diagnostic criteria have been simplified, the diagnostic accuracy has decreased. Although the initial set of cri teria may be timeconsuming to assess in clinical high throughput laboratories, our studies indicate that the inclusion of CSF analysis in cellbased assays is sufficient to raise the sensitivity and specificity of testing close to those of the three 'gold standard' criteria.
These limitations and variation of clinical criteria to define a disease could explain different results among investigators. For example, a study involving a cellbased assay showed that three of 46 (6.5%) patients with schizo phrenia had serum NMDAR antibodies (NR subunit not specified), whereas another study using the three cri teria outlined above found that none of 100 patients with schizophrenia had IgG NR1 antibodies (which are typical ly associated with antiNMDAR encephalitis). 103 Guidelines for antibody identification A recently published review 104 included response to immunotherapy as a component of criteria to define dis orders related to cellsurface antigens. However, patients with syndromes of unknown aetiology only have restricted access to empirical immunotherapy, making those criteria impractical. Furthermore, patients with rapidly progressive encephalopathy and inflam matory CSF changes-as occurs, for example, in CNS angiitis-may respond to empirical immunotherapy 105 and, conversely, patients with encephalitis and anti bodies against cellsurface antigens do not always respond to immunotherapy. 4, 49 Together, these factors could result in misclassification of disorders associated with antibodies to neuronal cellsurface proteins.
In our opinion, a disorder qualifies as being related to neuronal cellsurface antigens only when reactiv ity to such antigens is demonstrated (Figure 3) . 106 CSF analysis was crucial in our identification of novel anti gens, including NMDAR, 1 AMPAR, 2 GABA B receptor, 3 mGluR5, 8 neurexin, 107 and LGI1 and Caspr2. 4 Indeed, the first clue that eventually led to immunoprecipitation of these antigens arose from careful selection of patients with similar syndromes to one another and CSF reactiv ity to the neuropil of rat brain. The patterns of serum immuno staining in the same patients were more vari able than those of CSF, owing to nonspecific background staining, the presence of other antibodies, or alteration of reactivity by intravenous immunoglobulin or plasma exchange, which are sometimes used empirically to treat suspected autoimmune disorders.
Selection of patients with the same phenotype is crucial to avoid confusing results and allow antigen characteriza tion. For example, Caspr2 was recently reported to be an autoantigen in idiopathic cerebellar ataxia. 108 However, the index case had prominent limbic encephalitis, and in subsequent studies peripheral nerve hyperexcitability was identified (L. Bataller, personal communication). Among other patients with antiCaspr2 antibodies, only two had isolated cerebellar dysfunction without other auto immune symptoms and neither of these patients' serum reacted with tissue from the cerebellum, where Caspr2 is strongly expressed. 5 
Conclusions and future directions
Several categories of neuronal autoantibody targets exist, including cytoplasmic or nuclear antigens, intracellular synaptic proteins, and the more recently described cell surface or synaptic proteins. Cellsurface and synaptic proteins are particularly interesting because the associ ated antibodies seem to be pathogenic, and they produce symptoms that are more responsive to immunotherapy than those related to intracellular antigens. Furthermore, such antibodies are associated with syndromes that resemble genetic or pharmacological models in which the corresponding antigen is disrupted. The discovery of these disorders has led to the development of diagnostic tests which, although highly specific, have some limita tions when CSF is excluded from analysis. The use of serum and CSF is important not only for the diagnosis of known disorders, but also for the characterization of new autoantigens, as shown in our algorithm for antibody and antigen interpretation (Figure 3 ). In addition to the disorders described here, other syn dromes mediated by neuronal antibodies are likely to exist, and not all of these syndromes may show the clas sical symptoms of rapidly progressive encephalitis with CSF pleocytosis. Indeed, serum IgA antibodies against NMDARs were recently identified in a group of patients who presented with slowly progressive cognitive decline, and CSF that was normal or showed mild abnormalities in routine clinical tests. 109 Many questions about these disorders remain unan swered. For example, the trigger of the autoimmune response in many patients is unknown. As discussed above, only a fraction of patients with Hu antibodies develop symptoms, and most patients with ovarian tera tomas do not develop NMDARtargeted autoimmunity. Why do the usual mechanisms of selftolerance fail in other patients? And how does the antibody response become established in the CNS? 110 Robust intrathecal antibody synthesis usually accompanies some of these disorders, and migration of B cells into the CNS might be necessary for symptoms to occur. Could this event be targeted to prevent symptoms? The answers to these questions may result in new therapies.
Animal models of syndromes related to neuronal anti bodies would allow pathogenesis and treatments to be further explored, but recreation of some immunological findings or symptoms in animals does not necessarily equate to a disease model, particularly when the target antigen is behind the blood-brain barrier. 17, 21 Infusion of antibodies directly into the CSF of animals does not entirely overcome this problem, as such antibodies might not access the brain parenchyma. Additional strategies include development of a Bcell and/or Tcell response to various antigens in knockout animals for the same antigens and then transferring the B cells or T cells to wildtype animals. 19 Prompt immunotherapy is often associated with improved outcomes in encephalitis associated with anti bodies to cellsurface antigens, 4, 47 but which therapies (plasma exchange, intravenous immunoglobulin, ster oids, cyclophosphamide or rituximab) provide the great est benefit is unknown. A preliminary report has found that 44% of patients with antiNMDAR encephalitis fail firstline therapies, but secondline therapies (rituxi mab and cyclophosphamide) are usually effective. 111 As increasing numbers of patients with neuronal anti bodies are identified, clinical trials should be conducted to determine the optimal treatments for these disorders. Towards this goal, a trial of prolonged immunotherapy with rituximab in patients with antiNMDAR encepha litis has recently been approved by the NIH (Principal Investigators: A. Nath and J. Dalmau). With continued improvements in diagnosis and treatment, increasing numbers of patients with these disorders will live long and productive lives.
Review criteria
Articles were selected by searching the PubMed database for peer-reviewed papers containing the names of the various intracellular antigens (for example, "Hu" and "Ma") or the names of cell-surface or synaptic receptors (for example, "NMDA receptor") together with "antibodies" or "autoimmune" or "autoimmunity" that were published in English during the time period ending in March 2012. For some antigens, multiple names have been used in the literature, all of which were included as search terms.
